Magnetar Financial LLC Mirati Therapeutics, Inc. Transaction History

Magnetar Financial LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$41.99 - $62.38 $35 Million - $52 Million	834,390 New	834,390 $49 Million
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $799,312 - $1.19 Million	21,875 New	21,875 $813,000
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $238,797 - $540,953	-6,098 Reduced 43.85%	7,807 $524,000
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $1.05 Million - $2.1 Million	13,905 New	13,905 $1.14 Million
Q3 2021 Nov 12, 2021	SELL	$132.13 - $177.45 $235,587 - $316,393	-1,783 Closed	0 $0
Q2 2021 Aug 06, 2021	BUY	$144.0 - $179.73 $256,752 - $320,458	1,783 New	1,783 $288,000
Q1 2021 May 14, 2021	SELL	$158.92 - $221.61 $591,023 - $824,167	-3,719 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$162.05 - $240.27 $602,663 - $893,564	3,719 New	3,719 $817,000
Q1 2020 May 15, 2020	SELL	$69.78 - $116.21 $108,438 - $180,590	-1,554 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$70.76 - $128.86 $109,961 - $200,248	1,554 New	1,554 $200,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Magnetar Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Magnetar Financial LLC with notifications on news.